Abstrait

Senior Skilled Nursing Participants' Biocompatibility to Three Different Influenza Vaccines Against Homologous and Heterologous Strains

Richard J. Webby

We looked at how well the MF59 adjuvant in the influenza vaccine protects older people living in institutions from drifting influenza viruses [1]. Hemagglutination inhibition (HI) assays were used to retest sera from a randomised research comparing MF59-adjuvanted (Sub/MF59), virosomal (SVV), and split vaccinations. The GMTs against homologous A/ H3N2 and B and both drifting A strains were considerably higher for Sub/MF59 than split, and corrected postvaccination HI antibody titres were significantly greater with Sub/MF59 than SVV for all strains. For all A influenza strains, Seroprotection rates and mean-fold titer increases were generally higher with Sub/MF59. [2] In comparison to traditional virosomal and split vaccinations, MF59-adjuvanted influenza vaccine generated higher and broader immune responses in older patients with chronic illnesses, especially for A/H1 and A/ H3 strains, potentially indicating that delivering therapeutic benefit during antigenic mismatch seasons.